<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192449</url>
  </required_header>
  <id_info>
    <org_study_id>CIVETAN-IIET-ALB01</org_study_id>
    <nct_id>NCT03192449</nct_id>
  </id_info>
  <brief_title>Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole</brief_title>
  <official_title>Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole and Its Metabolites in Non-infected Human Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Nacional de Salta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CIVETAN CONICET, Facultad de Ciencias Veterinarias, UNCPBA. Tandil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional de Salta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mass drug administration (MDA) of albendazole (ABZ) to school-age and pre-school-age children
      is the currently recommended strategy for controlling soil-transmitted helminthiasis (STH) in
      endemic areas. Recent mathematical modelling suggests that community-wide MDA will be
      required in order to interrupt transmission of STH. DEWORM3 aims to determine the feasibility
      of eliminating STH through expanded and intensified MDA strategies. In order to ensure
      rigorous trial results, it is crucial that the definition of such MDA coverage is informed by
      unbiased, empirical data. The Centro de Investigaci√≥n Veterinaria de Tandil (CIVETAN) and
      Instituto de Investigaciones en Enfermedades Tropicales Universidad Nacional de Salta
      collaborate on scientific research related to pharmacokinetic studies of ABZ.

      This proposal describes the request for funding from DEWORM3 to conduct a study of the serum
      pharmacokinetic characteristics and urinary excretion of ABZ and its metabolites in
      non-infected human volunteers to better understand the use of urinary analysis of ABZ as a
      measure of MDA adherence in the context of DEWORM3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective 1.To characterize the plasma disposition kinetics of ABZ and its main metabolites
      (ABZ sulphoxide and ABZ sulphone) in non-infected human volunteers.

      Objective 2. To characterize the pattern of albendazole (ABZ) and its main metabolites (ABZ
      sulphoxide and ABZ sulphone) urinary excretion in non-infected human volunteers.

      Objective 3. To determine the optimal and the longest period time after treatment where
      either ABZ and/or its metabolites can be measured in urine as an indirect assessment of an
      individual's adherence to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Actual">January 20, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pharmacokinetics</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Albendazole in urine</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Urinary excretion of albendazole (ABZ) and its main metabolites (ABZ sulphoxide and ABZ sulphone) in non-infected human volunteers. PK parameters (Cmax, AUC, Tmax) from levels measured through HPLC</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Soil Transmitted Helminthiasis</condition>
  <condition>Neglected Tropical Diseases</condition>
  <arm_group>
    <arm_group_label>Albendazole 400mg p.o. single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole.</intervention_name>
    <description>Single dose 400mg orally</description>
    <arm_group_label>Albendazole 400mg p.o. single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Weight between 45 and 75 Kg.

          2. Physical exam without significant abnormal findings.

        Exclusion Criteria:

          1. Intake of ABZ or other benzimidazole drugs within the last 30 days.

          2. Malabsorption or other GI syndromes that could compromise the tolerability or
             absorption of ABZ.

          3. History of hypersensitivity or intolerance to ABZ or its inactive ingredients.

          4. Acute clinical conditions.

          5. Pregnancy or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro J Krolewiecki, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Nacional de Salta</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Nacional de Salta</investigator_affiliation>
    <investigator_full_name>Alejandro Krolewiecki</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication in peer review journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

